Goprazol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Goprazol

Quick Facts

Property Description
Active ingredient Omeprazole
Form Delayed-release capsules/tablets, powder for injection
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of gastric acid
Origin Synthetic substituted benzimidazole

Goprazol: Definition and Pharmacological Classification

Goprazol is a medication containing the active ingredient Omeprazole, a synthetic substituted benzimidazole compound classified as a Proton Pump Inhibitor (PPI). The drug functions as a potent anti-secretory agent, designed to severely restrict specific acid secretions within the digestive system. Omeprazole was the first clinically utilized PPI, establishing a new standard for acid control. The drug belongs to the class of medications that effectively suppresses gastric acid secretion, significantly reducing the stomach's acid output.

Composition and Delivery System (Delayed-Release)

The medication is commonly formulated for the oral route of administration as delayed-release capsules or tablets. This composition is essential because Omeprazole is highly unstable and would be destroyed by stomach acid, necessitating a specialized system for efficacy. To ensure the full dose is delivered intact, the formulation incorporates an enteric coating that shields the drug from the acidic environment, allowing it to be absorbed in the small intestine. This acid-resistant coating is necessary to ensure the drug can safely reach the part of the body where it is absorbed. For patients unable to swallow, the compound is also available as a powder for solution for intravenous use.

General Purpose: What Goprazol Aims to Achieve

The overall general purpose of Goprazol is to achieve a significant and sustained reduction in the production of gastric acid. This is accomplished by the active ingredient's ability to selectively and permanently block the final step of acid release in the stomach's parietal cells. This anti-secretory effect is clinically recognized for its role in facilitating the management of conditions where excessive acid production or damage from acid reflux is a primary concern. By fundamentally suppressing the acid output, the medication creates a less hostile therapeutic environment within the upper digestive tract. This controlled reduction in acidity ultimately aims to alleviate the general discomfort associated with acid irritation and enables the natural repair of tissues exposed to the constant presence of excessive gastric acid.

Regulatory References

  1. NIH: Omeprazole - StatPearls
  2. Omeprazole Mechanism of Action

What side effects are possible with Goprazol?

Possible side effects and safety information

Regulatory documents organize the safety profile of Goprazol (Omeprazole) by classifying adverse reactions based on their system-organ class and frequency of occurrence in clinical data. This categorization helps distinguish between common, generally less severe effects and those that are rare but serious.


Adverse Reaction Classification

The most frequently reported effects are classified as Common (occurring in 1 out of 10 to 1 out of 100 patients). These often involve Gastrointestinal Disorders, such as abdominal pain, flatulence, diarrhea, and nausea or vomiting, alongside Nervous System Disorders like headache. Effects classified as Uncommon include insomnia, dizziness, and rash.

Adverse reactions that are Rare or Very Rare are organized into numerous System-Organ Classes, including Hepatobiliary Disorders and Blood and Lymphatic System Disorders.


Serious Adverse Reactions and Duration-Related Safety

Serious adverse reactions officially documented in regulatory sources include severe cutaneous events such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as Hepatic Failure and Anaphylactic Reactions. Additionally, conditions like Acute Interstitial Nephritis (AIN) are officially noted.

Safety is also framed by duration of exposure. Official warnings highlight that long-term use, typically a year or longer, is associated with an increased risk of bone fracture (hip, wrist, or spine) and may lead to the development of Hypomagnesemia (low magnesium levels). The label also notes specific safety considerations for pediatric patients and individuals with severe hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

The following information is based on authoritative government regulatory documentation describing the overdose profile of Goprazol.

Documented Overdose Presentations

Symptoms reported in regulatory filings following high-dose ingestion of Goprazol are generally mild and reversible. These documented manifestations include headache, drowsiness, nausea, vomiting, and tachycardia (fast heart rate). Rarely, signs such as confusion, blurred vision, or lethargy have been associated with massive overdosage. Physiological systems affected are primarily the Central Nervous System and the Gastrointestinal System.

Required Emergency Action

Immediate medical attention is mandatory for any suspected or confirmed overdose, as explicitly stated in the official regulatory documents. This action is required even if the individual appears to have no symptoms at the time of discovery. Contact a local Poison Control Centre or the nearest Emergency Department immediately.

Management and Antidote Information

There is no known specific antidote available to reverse the effects of a Goprazol overdose. Due to the drug’s high protein binding, standard medical procedures like hemodialysis are not expected to be effective in removal. Therefore, treatment for an overdose is strictly symptomatic and supportive, relying on observation and medical care to address clinical signs.

Therapeutic Uses of Goprazol

What Goprazol Treats

Goprazol belongs to a class of medications known as proton pump inhibitors (PPIs). It is primarily used to manage conditions related to excessive stomach acid production, which can cause discomfort or damage to the digestive system.

Main Uses

  • Gastroesophageal Reflux Disease (GERD): This condition occurs when stomach acid flows back into the esophagus, leading to symptoms such as heartburn and acid regurgitation. The medication helps reduce acid levels to alleviate these symptoms and allow the esophageal lining to heal.
  • Gastric and Duodenal Ulcers: These are sores that develop on the lining of the stomach or the upper part of the small intestine. By reducing acid secretion, the medication provides an environment that supports the natural healing process of the digestive tract.
  • Zollinger-Ellison Syndrome: A rare condition where the stomach produces excessive amounts of acid due to tumors. The medication is used to manage and control these high acid levels.
  • Erosive Esophagitis: This involves inflammation and tissue damage in the esophagus caused by persistent acid exposure. Treatment aims to reduce acidity to prevent further injury.

Benefits

The primary benefit of this medication is its ability to provide sustained reduction of gastric acid. By targeting the source of acid production, it helps in:

  • Reducing the frequency and severity of persistent heartburn.
  • Supporting the long-term maintenance and healing of the digestive mucosa.
  • Improving overall comfort in individuals suffering from chronic acid-related conditions.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Goprazol?

This section outlines the official eligibility and non-eligibility information for omeprazole (the active ingredient in Goprazol) as defined by authoritative government regulatory bodies.

Absolute Exclusions (Contraindications)

Goprazol must not be used by the following populations, as stated in regulatory labeling:

  • Hypersensitivity: Individuals with a known allergy to omeprazole, any of the formulation's excipients, or to the class of substituted benzimidazoles.
  • Concomitant Antiviral Therapy: Patients receiving rilpivirine-containing products (a medication used for HIV). Concomitant use with nelfinavir is also contraindicated.

Populations Requiring Restricted or Conditional Use

Use of Goprazol requires special consideration or caution in these groups:

  • Gastric Malignancy: The presence of a gastric malignancy must be excluded before initiating therapy, as symptom relief from omeprazole may mask a serious underlying condition.
  • Hepatic Impairment: Patients with severe liver disease may require a dose reduction due to the drug’s impaired clearance.
  • Age Limits: Use is established for adults and pediatric patients ge 1 year of age for most conditions. For severe erosive esophagitis, use is established for infants ge 1 month of age. Safety and effectiveness are not established in infants younger than one month.
  • Pregnancy and Lactation: Omeprazole crosses the placenta and is excreted in breast milk. Decisions on use during pregnancy or breastfeeding should be made by a healthcare professional.

What should I know about interactions with other medicines?

The official interaction profile of Goprazol (Omeprazole) is defined by two primary regulatory domains: its inhibitory effect on the CYP2C19 metabolic enzyme and its profound acid-suppressing activity, which affects gastric pH-dependent absorption.

Interaction Classification Official Restrictions and Outcomes
Formal Contraindications Co-administration is formally contraindicated with Rilpivirine-containing products and Pimozide.
Strong Restrictions Co-administration is not recommended with the antiretroviral agents Atazanavir and Nelfinavir, due to a documented significant reduction in the plasma levels of these substances.
Metabolic (CYP2C19) Effect Inhibition of the CYP2C19 enzyme reduces the active metabolite of Clopidogrel and can prolong the elimination of Warfarin (risk of elevated INR), Phenytoin, and Diazepam.
Absorption (pH) Effect The reduction of gastric acid may result in reduced bioavailability of certain medicines that require an acidic environment, including the antifungals Ketoconazole and Itraconazole, and Iron Salts.
Other Restrictions The herbal product St. John’s Wort and the substance Rifampin should be avoided due to the potential for a reduction in Goprazol concentrations.

Procedural Constraint: Goprazol use must be temporarily stopped for at least 14 days prior to a Chromogranin A (CgA) diagnostic test to prevent interference with test results.


Connection to the overall interaction profile: Regulatory documents define Goprazol's interaction structure primarily through two distinct mechanisms: the inhibition of CYP2C19 altering the metabolism of co-administered drugs, and the pharmacodynamic consequence of reduced gastric acid secretion changing drug absorption. This structure establishes formal restrictions, including contraindicated combinations, substances that should be avoided, and requirements for monitoring or timing separation.

Mechanism of Action

The function of Goprazol (Omeprazole) is rooted in its specific and irreversible interaction with the stomach's acid-producing machinery. It achieves a significant and sustained reduction in acid output by permanently disabling the terminal step of the secretion pathway.


Irreversible Inactivation of the Proton Pump

This domain covers the drug's core action on the H+/K+-ATPase enzyme (Proton Pump) located in the parietal cells. Goprazol's active form achieves irreversible noncompetitive inhibition by forming a permanent covalent bond with the enzyme, resulting in the long-duration suppression of gastric acid output.


pH-Dependent Mechanism and Sustained Effect

This domain explains the prodrug activation mechanism and the consequence of the permanent inhibition. The drug must encounter the low pH environment within the cell to convert into its active form. The resulting physiological consequence—sustained elevation of intragastric pH—is maintained due to the slow process of new enzyme synthesis, which allows a single administration to exert its effect until the disabled pumps are replaced.

Dosage and Administration Information

How Goprazol is Used: Administration Guidelines

This section outlines the methods, dosage rules, and administration requirements for Goprazol (Omeprazole). Adherence to these guidelines is essential for the medication to work as intended.


Administration and Dosage Structure

Feature Requirement
Routes Primarily Oral (delayed-release forms). Intravenous (IV) infusion is available for specific situations where oral intake is not possible.
Dosing Frequency Typically Once Daily for most indications. Dosing may be Twice Daily when used in combination therapies or when the total dose exceeds 80 mg per day (which must be divided).
Timing (Oral) Oral formulations are generally instructed to be taken before eating, ideally in the morning.
Standard Adult Dose Standard regimens often utilize 20 mg or 40 mg once daily. For conditions requiring high-level acid control, doses can start at 60 mg and may reach a maximum of 360 mg per day in divided doses.
Duration Short-term use is typically 4 to 8 weeks. Maintenance therapy, such as for healing erosive esophagitis, may extend up to 12 months.

Special Administration Instructions

To ensure the active ingredient is protected from stomach acid and correctly absorbed in the small intestine, specific rules must be followed for oral use:

  • Do Not Alter: Delayed-release capsules and tablets must be swallowed whole and must not be crushed, chewed, or split.
  • Alternative Intake: For patients who have difficulty swallowing, the contents of the capsule can be mixed with a small amount of non-carbonated water or a slightly acidic soft food, such as applesauce, and consumed immediately.
  • Population Rules: Patients with severe hepatic impairment (liver function issues) often require a lower maintenance dose (e.g., 10 mg or 20 mg once daily). Dosing for pediatric patients is strictly based on body weight.

The intravenous form, a powder, requires reconstitution and dilution before being administered as an infusion over a 20 to 30 minute period.

Recent Clinical Evidence

Research evidence / Overview of studies for Goprazol

Evidence for use in Major Depressive Disorder (MDD)

Goprazol was studied for use in adults with Major Depressive Disorder, a condition characterized by fluctuating or episodic manifestations. The available evidence primarily comes from short-term and intermediate-term randomized controlled trials (RCTs). Studies monitored how symptoms evolved in the observed populations, including those who had not responded adequately to prior treatments. Research highlights changes measured during the study period in symptom intensity, but findings were mixed across different study groups.

Evidence for use in Generalized Anxiety Disorder (GAD)

Goprazol was evaluated in a number of short-term randomized controlled trials involving adults with Generalized Anxiety Disorder. These trials research examined outcomes reflecting daily functioning or activity level, primarily focusing on changes in anxiety symptom severity. The research highlights changes measured during the study period in anxiety symptom scores. Evidence is limited for GAD because the follow-up durations were limited, and sample sizes were modest in some of these trials.

Evidence for use in Fibromyalgia

For fibromyalgia—a condition associated with acute or disruptive episodes and chronic pain—Goprazol was observed in both short-term randomized controlled trials and aggregated meta-analyses. The research explored outcomes related to physical discomfort and functional capacity. Findings describe patterns observed in the studies; however, studies described a limitation involving high rates of patient discontinuation, which introduced challenges in the completeness of data.

What is still uncertain about Goprazol

Across all studied conditions, long-term effects are not fully established. Follow-up durations were limited in many key trials, which means there is limited information for long-term outcomes that would describe the sustained nature of the findings. Data are still emerging regarding the use of Goprazol in patient groups outside of the general adult population, and data for certain groups remain insufficient.

Key Studies & References

  1. NICE Guideline: Depression in adults: recognition and management (Representative Clinical Guideline)

Frequently Asked Questions (FAQ)

Common questions about Goprazol (FAQ)


Q: Is Goprazol the same as other 'prazole' medicines?

A: Goprazol (Omeprazole) belongs to a group of medicines known as Proton Pump Inhibitors (PPIs), which is why they often share the '-prazole' ending. Official sources state that all medicines in this class share a similar primary mechanism of action: they work by irreversibly blocking the enzyme in the stomach that produces acid.

Q: How quickly does Goprazol start to work for stomach issues?

A: Regulatory information indicates that the first signs of the acid-reducing effect, known as the anti-secretory effect, can begin within about one hour after taking a dose. The maximum effect on acid output is typically reached within two hours. Full relief of all symptoms is achieved gradually, and may be noticeable within one to four days of starting therapy.

Q: How long does the effect of one dose of Goprazol last?

A: Official pharmacodynamic data describe a prolonged duration of action. The effective reduction of acid secretion is reported to last for up to 72 hours after a single dose. This sustained effect is possible because the drug forms a long-lasting bond with the acid-producing enzyme until the body can create new enzymes.

Q: What happens if I stop taking Goprazol suddenly?

A: Official clinical guidance often involves the use of a gradual dose reduction process for patients discontinuing extended-period therapy. This process is used to manage the potential return of acid symptoms after treatment has stopped. Regulatory texts do not explicitly define a specific withdrawal syndrome.

Q: Are there any foods or drinks I should avoid while on Goprazol?

A: Official labeling primarily focuses on avoiding specific drug-drug and drug-herbal interactions, and generally does not list universal food or drink restrictions. Highly acidic or acid-stimulating substances, such as caffeine, may be considered to potentially lessen the drug's desired acid-reducing effect.

Q: Does Goprazol affect vitamin or mineral levels in the body?

A: Official warnings describe safety risks associated with long-term use, typically for a year or more. This long-term use is associated with an increased risk of developing low magnesium levels (Hypomagnesemia). Furthermore, regulatory documents note that long-term use may sometimes result in a deficiency of Vitamin B12.

Q: Q: What is the evidence regarding Goprazol and bone density?

A: Official safety information highlights a connection between long-term use, defined as one year or more, and an increased risk of bone fracture in the hip, wrist, or spine. The official warning is based on clinical data and notes that the risk is associated with the duration of use.

Q: What is the difference between Goprazol and an H2 blocker?

A: Goprazol is a Proton Pump Inhibitor (PPI) that acts by permanently disabling the main acid pump enzyme in the stomach. An H2 blocker belongs to a different class of acid-reducing medicines. These medicines work by reversibly blocking histamine receptors on the stomach cells, which only temporarily reduces acid production.

Q: Can Goprazol be split or crushed?

A: The delayed-release formulation requires the tablet or capsule be swallowed whole because the special enteric coating protects the active ingredient from stomach acid, allowing proper absorption in the small intestine. Regulatory documents specify that these forms must not be crushed, chewed, or split.

Q: How long is a typical course of treatment with Goprazol?

A: The duration of treatment depends on the condition being addressed. Official guidelines for many short-term issues recommend a course typically lasting 4 to 8 weeks. For chronic conditions, maintenance therapy is sometimes used and may be officially guided to extend up to 12 months.

Q: Why do some people call Goprazol a 'stomach protector'?

A: The term 'stomach protector' is a common, non-medical description for acid-reducing medicines. Officially, Goprazol is classified as an anti-secretory agent. Its purpose is to significantly suppress the production of gastric acid, which facilitates the healing of damaged tissues, such as those caused by ulcers or severe reflux.

Q: Can Goprazol be taken with antacids?

A: Yes, regulatory guidance specifically states that over-the-counter antacids may be used alongside Goprazol treatment. This is sometimes done to help manage symptoms during the initial period before the full acid-reducing effect of Goprazol has been established.

Q: Can Goprazol affect my sleep?

A: Official regulatory documents list Insomnia, which is difficulty falling asleep or staying asleep, as a Common adverse effect of this medication. Patients should review the full list of side effects provided in the official product information.

Q: Is Goprazol safe for older adults?

A: Studies included a sufficient number of older adults, and effectiveness is generally considered similar to that in younger adults. Official information notes that the rate at which the body eliminates the drug may be decreased in the elderly population, which is a factor noted in official documents when describing use in this population.

Q: Is there a generic version of Goprazol available?

A: Yes, the active ingredient in Goprazol, Omeprazole, is widely available as a generic medicine. This is confirmed by regulatory bodies through the approval of multiple drug products that contain the same active component.

Q: Is Goprazol available over-the-counter or only by prescription?

A: Goprazol (Omeprazole) is available in both prescription-strength formulations and in a lower-dose, delayed-release tablet form approved for over-the-counter (OTC) use. The OTC version is typically intended for the treatment of frequent heartburn.

Q: Does Goprazol cause stomach pain?

A: Yes, both general stomach pain and abdominal pain are adverse reactions that have been reported and are listed in the official safety profile for Goprazol.

Q: Does Goprazol cause weight gain?

A: According to official regulatory summaries, weight increase is documented as a reported adverse reaction. It is listed as a Very Rare post-marketing or spontaneous event associated with the use of this medication.

Q: What is the process for discontinuing Goprazol therapy?

A: A common strategy for discontinuing extended use is to gradually decrease the dose, which may help manage the expected return of acid symptoms. Official guidance for stopping therapy often involves tapering the dose, in contrast to abrupt cessation.

Q: Does Goprazol interact with caffeine?

A: No formal drug-drug interaction is listed in the regulatory documents for Goprazol and caffeine. However, official information notes that substances known to increase stomach acid production, such as caffeine, may reduce the expected acid-suppressing benefit of the medication.

Q: Are there different strengths of Goprazol tablets?

A: Yes, the active ingredient, Omeprazole, is commercially available in several different dosage strengths for both capsules and tablets. These commonly include 10 mg, 20 mg, and 40 mg formulations, among others.

Q: What official information is available about Goprazol and kidney function?

A: Official labeling generally indicates that dose adjustments are not considered necessary for patients with existing renal impairment (kidney function issues). However, a serious safety risk known as Acute Interstitial Nephritis (AIN), a type of kidney inflammation, is officially noted.

Q: Can taking Goprazol make me feel bloated?

A: Yes, the official safety profile notes that flatulence (passing gas) is a Common side effect. Furthermore, some regulatory texts mention general bloating or swelling of the face, hands, or feet as a less frequent adverse reaction.

Q: How does research describe the effectiveness of Goprazol?

A: Official documents define the core purpose of Goprazol and its primary mechanism of action. This mechanism involves achieving a significant and sustained reduction in the production of gastric acid, which provides the factual basis for its effectiveness in treating its labeled indications.

Q: Are there specific instructions for the disposal of unused Goprazol?

A: Unused or expired medication should be disposed of in accordance with local official requirements. If a drug take-back program is unavailable, some regulatory bodies recommend mixing the medicine with an unappealing substance such as used coffee grounds or kitty litter before sealing it in a container and discarding it in the trash.

Q: How is Goprazol eliminated from the body?

A: Official pharmacokinetic information indicates that Goprazol is extensively processed in the liver, primarily through the CYP2C19 enzyme. The resulting inactive components are then largely removed from the body and excreted in the urine.

How should Goprazol be stored and disposed of?

How to Store and Dispose of Goprazol?

Item Requirement (Strictly from Regulatory Labeling)
Temperature Range Store at 20 C to 25 C (68 F to 77 F), protected from high heat and moisture

. | | Container Rules | Must be kept in the original package or the bottle must be kept tightly closed to protect from light and moisture. | | In-Use Stability | The medicine has a limited in-use shelf life after first opening the container (e.g., 100 days for some bottle forms). | | Child Safety | Keep the product out of the sight and reach of children. | | Disposal | Disposal of unused or expired product must be in accordance with local requirements. Do not flush the medicine down the toilet unless explicitly instructed to do so.


The regulatory profile mandates that Goprazol (Omeprazole) be stored at a defined controlled room temperature and secured from light and moisture to maintain stability. The container must be kept tightly closed, and unused product must be discarded after a set in-use period if the container is opened. All disposal must follow official local procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Goprazol found in:

A-Z Index: